

CURE VanEck Genomics and Healthcare Innovators UCITS ETF

Fund Details

| | |
|---------------------------|--------------------------------------------------------------------|
| Base Currency | USD |
| Inception Date | 02 September 2022 |
| Domicile | Ireland |
| Net Assets | USD 16.8M |
| Shares Outstanding | 740,000 |
| Total Expense Ratio | 0.35% |
| Product Structure | Physical (Full Replication) |
| UCITS Compliant | Yes |
| Rebalance Frequency | Semi-Annually |
| Distribution Frequency | None |
| Income Treatment | Reinvestment |
| Swiss Valor | 121031038 |
| ISA Eligibility | Yes |
| SIPP Available | Yes |
| Countries of Registration | AT, CH, DE, DK, ES, FI, FR, IE, IS, IT, LU, NL, NO, PL, PT, SE, UK |

Fund Description

31 January 2026


The VanEck Genomics and Healthcare Innovators UCITS ETF (CURE) is a UCITS-compliant exchange-traded fund that invests in a portfolio of equity securities with the aim of providing investment returns that closely track the performance of the MVIS®Global Future Healthcare ESG Index. The MVIS® Global Future Healthcare ESG Index is a global index that tracks the performance of companies that are involved in the genomic health care and electronic healthcare industries.



Performance History (%)

| | Month End as of 31 Jan 2026 | 1 MO* | 3 MO* | YTD* | 1 YR | 3 YR | 5 YR | 10 YR | INCEPTION | ETF |
|-----------------|-----------------------------|-------|-------|------|-------|------|------|-------|-----------|-----|
| ETF | | 1.64 | 1.62 | 1.64 | 11.49 | 1.26 | -- | -- | 3.49 | |
| MVFHCTR (Index) | | 1.66 | 1.69 | 1.66 | 11.86 | 1.63 | -- | -- | 3.83 | |

Past Performance as of 31 Dec 2025



| | 2021 | 2022 | 2023 | 2024 | 2025 |
|-----------------------------------------------------------|------|------|------|------|------|
| VanEck Genomics and Healthcare Innovators UCITS ETF | -4.8 | -5.1 | 17.7 | | |
| Benchmark Index (MVIS Global Future Healthcare ESG Index) | -4.6 | -4.8 | 18.1 | | |

Past performance does not predict future returns. Performance quoted represents past performance. Current performance may be lower or higher than average annual returns shown. Performance data is displayed on a Net Asset Value basis, in Base Currency terms, with net income reinvested, net of fees. Brokerage or transaction fees will apply. Returns may increase or decrease as a result of currency fluctuations. Investors must be aware that, due to market fluctuations and other factors, the performance of the ETFs may vary over time and should consider a medium/long-term perspective when evaluating the performance of ETFs. **Investing is subject to risks, including the possible loss of principal.** Source: VanEck.

*Reference periods indicate cumulative performance, not annualized.

Fund Data

| | |
|-----------------------|-----------|
| Number of Holdings | 46 |
| Price/Earnings Ratio* | 35.94 |
| Price/Book Ratio* | 4.22 |
| Weighted Avg. MCap | USD 33.0B |

* Last 12 Months

Country Breakdown

| | |
|---------------|--------|
| United States | 83.71% |
| China | 5.04% |
| Germany | 3.97% |
| Australia | 2.58% |
| Japan | 1.43% |
| Switzerland | 1.28% |
| Other/Cash | 1.98% |

CURE VanEck

Genomics and Healthcare Innovators UCITS ETF



Top 10 Holdings

31 January 2026

| | |
|-------------------------------|----------------|
| VERTEX PHARMACEUTICALS INC | 8.44% |
| REGENERON PHARMACEUTICALS INC | 8.16% |
| VEEVA SYSTEMS INC | 6.22% |
| NATERA INC | 5.94% |
| DEXCOM INC | 5.94% |
| ALNYLAM PHARMACEUTICALS INC | 5.43% |
| ILLUMINA INC | 5.25% |
| GUARDANT HEALTH INC | 4.36% |
| MODERNA INC | 4.33% |
| EXACT SCIENCES CORP | 4.06% |
| SUBTOTAL - TOP 10 | 58.11% |
| REMAINING HOLDINGS | 41.79% |
| OTHER/CASH | 0.10% |
| TOTAL | 100.00% |

For a complete up-to-date listing of Fund holdings, please visit www.vaneck.com

Trading Information

| EXCHANGE | TRADING CURRENCY | ISIN | EXCHANGE TICKER | BLOOMBERG TICKER | REUTERS TICKER | SEDOL | IOPV SYMBOL |
|-----------------------|------------------|--------------|-----------------|------------------|----------------|---------|-------------|
| LONDON STOCK EXCHANGE | USD | IE000B9PQW54 | CURE | CURE LN | CURE.L | BQFP700 | CUREUSIV |
| LONDON STOCK EXCHANGE | GBP | IE000B9PQW54 | CURG | CURG LN | CURG.L | BQFP711 | CUREUSIV |
| DEUTSCHE BÖRSE | EUR | IE000B9PQW54 | CURE | CURE GY | CURE.DE | BNG7JX1 | CUREUSIV |
| SIX SWISS EXCHANGE | CHF | IE000B9PQW54 | CURE | CURE SE | CURE.S | BNG7JZ3 | CUREUSIV |
| BORSA ITALIANA | EUR | IE000B9PQW54 | CURE | CURE IM | CURE.MI | BNG7JY2 | CUREUSIV |

Key Risks

Liquidity Risk: This risk exists when a particular financial instrument is difficult to purchase or sell. If the relevant market is illiquid, it may not be possible to initiate a transaction or liquidate a position at an advantageous or reasonable price, or at all. This is a factor to consider before investing in a Genomics ETF.

Equity Market Risk: The prices of the securities in a Genomics ETF are subject to the risks associated with investing in the securities market, including general economic conditions and sudden and unpredictable drops in value. An investment in the Fund may lose money.

Industry or Sector Concentration Risk: The Fund's assets may be concentrated in one or more particular sectors or industries. A Genomics ETF may be subject to the risk that economic, political or other conditions that have a negative effect on the relevant sectors or industries will negatively impact the Fund's performance to a greater extent than if the Fund's assets were invested in a wider variety of sectors or industries.

For more information on risks, please see the "Risk Factors" section of the relevant Fund's prospectus, available on www.vaneck.com.

IMPORTANT INFORMATION

This is marketing communication. Please refer to the prospectus of the UCITS and to the Key Information Document ("KID") before making any final investment decisions. These documents are available in English and the KIDs in local languages and can be obtained free of charge at www.vaneck.com, from VanEck Asset Management B.V. (the "Management Company") or, where applicable, from the relevant appointed facility agent for your country.

This information originates from VanEck (Europe) GmbH, which is authorized as an EEA investment firm under MiFID under the Markets in Financial Instruments Directive ("MiFID"). VanEck (Europe) GmbH has its registered address at Kreuznacher Str. 30, 60486 Frankfurt, Germany, and has been appointed as distributor of VanEck products in Europe by the Management Company. The Management Company is incorporated under Dutch law and registered with the Dutch Authority for the Financial Markets (AFM).

This material is only intended for general and preliminary information and shall not be construed as investment, legal or tax advice. VanEck (Europe) GmbH and its associated and affiliated companies (together "VanEck") assume no liability with regards to any investment, divestment or retention decision on the basis of this information.

VanEck Genomics and Healthcare Innovators UCITS ETF (the "ETF") is a sub-fund of VanEck UCITS ETFs plc, an open-ended variable capital umbrella investment company with limited liability between sub-funds. The ETF is registered with the Central Bank of Ireland, passively managed and tracks an equity index. The value of the ETF assets may fluctuate heavily as a result of the investment strategy. For details on the regulated markets where the ETF is listed, please refer to the Trading Information section on the ETF page at www.vaneck.com. Investing in the ETF should be interpreted as acquiring shares of the ETF and not the underlying assets.

MVIS® Global Future Healthcare ESG Index is the exclusive property of MarketVector Indexes GmbH (a wholly owned subsidiary of Van Eck Associates Corporation), which has contracted with Solactive AG to maintain and calculate the Index. Solactive AG uses its best efforts to ensure that the Index is calculated correctly. Irrespective of its obligations towards MarketVector Indexes GmbH ("MarketVector"), Solactive AG has no obligation to point out errors in the Index to third parties. VanEck's ETF is not sponsored, endorsed, sold or promoted by MarketVector and MarketVector makes no representation regarding the advisability of investing in the ETF. It is not possible to invest directly in an index.

Performance quoted represents past performance. Current performance may be lower or higher than average annual returns shown. Performance data for the Irish domiciled ETFs is displayed on a Net Asset Value basis, in Base Currency terms, with net income reinvested, net of fees. Returns may increase or decrease as a result of currency fluctuations. Investors must be aware that, due to market fluctuations and other factors, the performance of the ETFs may vary over time and should consider a medium/long-term perspective when evaluating the performance of ETFs.

Investing is subject to risk, including the possible loss of principal. Investors must buy and sell units of the UCITS on the secondary market via an intermediary (e.g. a broker) and cannot usually be sold directly back to the UCITS. Brokerage fees may incur. The buying price may exceed, or the selling price may be lower than the current net asset value. The indicative net asset value (iNAV) of the UCITS is available on Bloomberg. The Management Company may terminate the marketing of the UCITS in one or more jurisdictions. The summary of the investor rights is available in English at: [complaints-procedure.pdf\(vaneck.com\)](http://complaints-procedure.pdf(vaneck.com)). For any unfamiliar technical terms, please refer to [ETF Glossary | VanEck](#).

No part of this material may be reproduced in any form, or referred to in any other publication, without express written permission of VanEck.

© VanEck (Europe) GmbH